Enovis makes €155M binding offer for surgical robotics firm eCential
What's the deal? Enovis (NYSE: ENOV) has entered a binding offer to acquire French surgical robotics developer eCential Robotics, valuing the company at an upfront enterprise value of €155 million. Shareholders would receive about €176 million in cash at closing, plus up to €35 million in contingent consideration tied to milestones.
What's the endgame? Enovis wants to add robotic automation to its ASTRA platform. The deal complements its existing ARVIS augmented reality system and will establish a robotics centre of excellence in Grenoble, France.
The fine print: This is a binding offer, not yet a definitive agreement. Closing is expected by year-end 2026, subject to regulatory approvals and French works council procedures. Enovis will fund the deal with cash and its existing revolving credit facility.
What could go wrong? The acquisition carries costs. Enovis expects roughly 150 basis points of deal-related dilution to its adjusted EBITDA margin in 2027, partly offset by 50 basis points of underlying improvement — a net 100 basis point headwind.
Why the confidence? Enovis projects free cash flow conversion rising to 50% in 2027, exceeding $100 million, with further improvement in 2028 and 2029.
The signal: Medical device makers are moving to fold robotics and enabling technologies into their surgical platforms. By absorbing eCential, Enovis bets that automation and augmented reality will become standard features rather than optional add-ons.
Read more: stocktitan.net
Image credit: NavyMedicine
